A critical evaluation of crizanlizumab for the treatment of sickle cell disease

References

• Neel JV. The Inheritance of Sickle Cell Anemia. Science. 1949 Jul;110(2846):64–66.
   PubMed Web of Science ®Google Scholar
• Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annu Rev Genomics Hum Genet. 2018 Aug;19(1):113–147.
   PubMedGoogle Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Prim. 2018;4(1):18010. Internet.
   PubMedGoogle Scholar
• Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet. 2017 Jul;390(10091):311–323.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr;376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010 Apr;38(4 Suppl):S512–21.
   PubMed Web of Science ®Google Scholar
• Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013 Jan;381(9861):142–151.
   PubMed Web of Science ®Google Scholar
• Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128:1436–1438. United States.
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Haywood CJ. Mortality rates and age at death from sickle cell disease: u.S., 1979-2005. 433021. 2013;128(2):110–116.
   Google Scholar
• Lanzkron S, Carroll CP, Haywood CJ. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797–799.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005 May;79(1):17–25.
   PubMed Web of Science ®Google Scholar
• Guy A, Gourdou-Latyszenok V, Le Lay N, et al. Vascular endothelial cell expression of JAK2 V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica. 2019 Jan;104(1):70–81.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l -glutamine in sickle cell disease. N Engl J Med. 2018 Jul;379(3):226–235.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995 May;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Aug;381(6):509–519.
   PubMed Web of Science ®Google Scholar
• Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019 Jan;14(1):263–292.
   PubMedGoogle Scholar
• Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. Internet]. 2016 January 12. 2016 Feb 18;127(7):801–809. Available from https://pubmed.ncbi.nlm.nih.gov/26758915
   PubMed Web of Science ®Google Scholar
• Kutlar A, Embury SH. Cellular adhesion and the endothelium: p-selectin. Hematol Oncol Clin North Am. 2014 Apr;28(2):323–339.
   PubMed Web of Science ®Google Scholar
• Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997 Nov;337(22):1584–1590.
   PubMed Web of Science ®Google Scholar
• Matsui NM, Borsig L, Rosen SD, et al. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001 Sep 15;98(6):1955–1962. Internet.
   PubMed Web of Science ®Google Scholar
• Bennewitz MF, Jimenez MA, Vats R, et al. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight. 2017 Jan;2(1):e89761.
   PubMed Web of Science ®Google Scholar
• Polanowska-Grabowska R, Wallace K, Field JJ, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2392–2399.
   PubMed Web of Science ®Google Scholar
• Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011 Jan;117(2):727–735.
   PubMed Web of Science ®Google Scholar
• FDA. ADAKVEO (crizanlizumab): Highlights of prescribing information [Internet]. [ cited 2021 Aug 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
   Google Scholar
• Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002 Mar;99(5):3047–3051.
   PubMed Web of Science ®Google Scholar
• Bennewitz MF, Tutuncuoglu E, Gudapati S, et al. P-selectin–deficient mice to study pathophysiology of sickle cell disease. Blood Adv. 2020Jan22;4(2):266–273. Internet.
   PubMed Web of Science ®Google Scholar
• Höpfner M, Alban S, Schumacher G, et al. Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents. J Pharm Pharmacol. 2003 May;55(5):697–706.
   PubMed Web of Science ®Google Scholar
• Kutlar A, Ataga KI, McMahon L, et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol. 2012 May;87(5):536–539.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer announces phase 3 top-line results for rivipansel in patients with sickle cell disease experiencing a vaso-occlusive crisis [Internet]. [cited 2021 Aug 17]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis
   Google Scholar
• Biemond BJ, Tombak A, Kilinc Y, et al. Efficacy and safety of sevuparin, a novel non-anti-coagulant heparinoid, in patients with acute painful vaso-occlusive crisis; A global, multicenter double-blind, randomized, placebo-controlled phase 2 trial (TVOC01). Blood. 2019Nov13;134(Supplement_1):614. Internet.
   PubMedGoogle Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017Feb; 3765: 429–39.** The landmark phase II study, SUSTAIN of crizanlizumab in sickle cell disease that led to FDA approval.
   Web of Science ®Google Scholar
• Novartis. ADAKVEO (crizanlizumab-tmca) for IV infusion: full prescribing information [Internet]. [cited 2021 Aug 17]. Available from: https://www.novartis.us/sites/www.novartis.us/files/adakveo.pdf** Full prescribing information on crizanlizumab from Novartis.
   Google Scholar
• Novartis. New drug application to FDA for crizanlizumab [Internet]. [ cited 2021 Aug 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761128Orig1s000MultidisciplineR.pdf** New drug application for crizanlizumab submitted to Federal Drug Administration. Detailed pharmacokinetics and pharmacodynamics data.
   Google Scholar
• Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018 Nov;11(6):540–552.
   PubMed Web of Science ®Google Scholar
• Liles D, Smith-Whitley K, Brown C, et al. 1715 Pharmacokinetics/pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease and a history of vaso-occlusive crises: results from the phase ii, multicenter, open-label solace-adults study. In: 62nd ASH Annual Meeting and Exposition San Diego, CA, USA: 2020 Dec 5-8 [Internet]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper137434.html
   Google Scholar
• Kanter J, Liles DK, Smith-Whitley K, et al. Crizanlizumab 5.0 mg/kg exhibits a favorable safety profile in patients with sickle cell disease: Pooled data from two phase ii studies. Blood. 2019Nov13;134(Supplement_1):991. Internet.
   Google Scholar
• Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019 Jan;94(1):55–61.
   PubMed Web of Science ®Google Scholar
• Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020 Jun;40(6):535–543.
   PubMed Web of Science ®Google Scholar
• Liles DK, Cançado R, Kanter J, et al. Established prevention of vaso-occlusive crises with crizanlizumab is further improved in patients who follow the standard treatment regimen: Post-hoc analysis of the phase ii sustain study. Blood. 2018Nov29;132(Supplement 1):1082. Internet.
   Google Scholar
• Ataga KI, Kutlar A, DeBonnett L, et al. Crizanlizumab treatment is associated with clinically significant reductions in hospitalization in patients with sickle cell disease: Results from the sustain study. Blood. 2019 Nov 13;134(Supplement_1):2289. Internet.
   Google Scholar
• Smith W, Ataga K, Saraf S, et al. The effect of crizanlizumab on the number of days requiring opioid use for management of pain associated with vaso-occlusive crises in patients with sickle cell disease: results from the sustain trial. Blood. 2020 Nov 5;136:32–33.
   Web of Science ®Google Scholar
• Ghosh S, Flage B, Weidert F, et al. P-selectin plays a role in haem-induced acute lung injury in sickle mice. Br J Haematol. 2019;186:329–333.
   PubMed Web of Science ®Google Scholar
• Vats R, Kaminski TW, Ju E-M, et al. P-selectin deficiency promotes liver senescence in sickle cell disease mice. Blood. 2021May13;137(19):2676–2680. Internet.
   PubMed Web of Science ®Google Scholar
• Novartis. NCT03814746: Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients (STAND) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03814746
   Google Scholar
• Novartis. NCT03938454: a study to evaluate the safety and efficacy of crizanlizumab in sickle cell disease related priapism (SPARTAN) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03938454
   Google Scholar
• Novartis. NCT04053764: Study exploring the effect of crizanlizumab on kidney function in patients with chronic kidney disease caused by sickle cell disease (STEADFAST) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04053764
   Google Scholar
• Novartis. NCT03474965: Study of dose confirmation and safety of crizanlizumab in pediatric sickle cell disease patients [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03474965
   Google Scholar
• Novartis. NCT04097821: Platform study of novel ruxolitinib combinations in myelofibrosis patients (ADORE) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04097821
   Google Scholar
• Johns Hopkins University N. NCT04435184: Crizanlizumab for treating COVID-19 vasculopathy (CRITICAL) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04435184
   Google Scholar
• Washington University School of Medicine. NCT04611880: Crizanlizumab for treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL) [Internet]. [cited 2021 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04611880
   Google Scholar
• Cerletti C, Tamburrelli C, Izzi B, et al. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012 Mar;129(3):263–266.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001 Jan;103(4):491–495.
   PubMed Web of Science ®Google Scholar
• Spangrude GJ, Lewandowski D, Martelli F, et al. P-selectin sustains extramedullary hematopoiesis in the gata1low model of myelofibrosis. Stem Cells. 2016Jan1;34(1):67–82. Internet.
   PubMed Web of Science ®Google Scholar
• Zetterberg E, Verrucci M, Martelli F, et al. Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets. 2014;25(7):539–547.
   PubMed Web of Science ®Google Scholar
• Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1608–14.
   PubMed Web of Science ®Google Scholar
• Agrati C, Bordoni V, Sacchi A, et al. Elevated P-selectin in severe covid-19: Considerations for therapeutic options. Mediterr J Hematol Infect Dis. 2021;13(1):e2021016.
   PubMedGoogle Scholar
• Badawy SM, Thompson AA, Lai J-S, et al. Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017 Jul;15(1):136.
   PubMed Web of Science ®Google Scholar
• Yu Z, Blankenship L, Jaiyesimi I. Crizanlizumab in sickle cell disease. N Engl J Med. 2017;376:1795–1796. United States.
   PubMed Web of Science ®Google Scholar
• Kutlar A, Kanter J, Liles D, et al. Crizanlizumab, a P-selectin inhibitor, increases the likelihood of experiencing a sickle cell-related pain crisis while on treatment: results from phase II SUSTAIN study. In: European Hematology Association abstract [Internet]. European Hematology Association library; 2017. Available from: https://library.ehaweb.org/eha/2017/22nd/181741/abdullah.kutlar.crizanlizumab.a.p-selectin.inhibitor.increases.the.likelihood.html?f=m3s619830e1181
   Google Scholar
• Karki NR, Kutlar A. P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: a spotlight on crizanlizumab. J Pain Res. Internet]. 2021 Mar 30;14:849–856. Available from.;:. https://pubmed.ncbi.nlm.nih.gov/33833562
   PubMed Web of Science ®Google Scholar
• Thom H, Jansen J, Shafrin J, et al. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open. 2020 Sep;10(9):e034147.
   PubMed Web of Science ®Google Scholar
• Sharar SR, Sasaki SS, Flaherty LC, et al. P-selectin blockade does not impair leukocyte host defense against bacterial peritonitis and soft tissue infection in rabbits. J Immunol. [Internet]. 1993 Nov 1;151(9):4982 LP 4988. Available from 4988. Available from http://www.jimmunol.org/content/151/9/4982.abstract
   PubMed Web of Science ®Google Scholar
• Novartis. Novartis provides update on safety information about crizanlizumab. [Internet]. [cited 2021 Aug 17]. Available from: https://www.crizanlizumab.info/* Post marketing surveillance report on crizanlizumab, brief discussion on infusion related reactions.
   Google Scholar
• Karkoska K, Quinn CT, Clapp K, et al. Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. Am J Hematol. 2020 Dec 1;95(12):E338–9. Internet.
   PubMed Web of Science ®Google Scholar
• Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600–609.
   PubMed Web of Science ®Google Scholar
• Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020Jun19;4(12):2656–2701. Internet.
   PubMed Web of Science ®Google Scholar
• Salcedo J, Young CM, Bulovic J. The total direct cost of healthcare in the United States in patients with sickle cell disease: a propensity score matched analysis. Blood. 2019 Nov 13;134(Supplement_1):4671. Internet.
   Google Scholar
• Shah N, Bhor M, Xie L, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. Health Qual Life Outcomes. 2019;17(1):155. Internet.
   PubMed Web of Science ®Google Scholar
• Jessica S, Melissa K, Emily AS, et al. Income and poverty in the United States: 2019 [Internet]. Available from: https://www.census.gov/content/dam/Census/library/publications/2020/demo/p60-270.pdf
   Google Scholar
• Bradt P, Spackman E, Synnott P, et al. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. Institute for Clinical and Economic Review, January 23, 2020 [Internet]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SCD_EvidenceReport_031220-FOR-PUBLICATION.pdf
   Google Scholar
• Onasanya O, Park JE, Zafari Z. PCN125 NOVEL ANTI-SICKLING AGENTS AND HYDROXYUREA VERSUS CHRONIC TRANSFUSIONS IN SICKLE CELL DISEASE: a COST-EFFECTIVENESS ANALYSIS. Value Heal. 2020 May 1;23:S45.
   Web of Science ®Google Scholar
• Majumdar S, Webb S, Norcross E, et al. Stroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia. Pediatr Blood Cancer. 2013Jul1;60(7):1192–1197. Internet.
   PubMed Web of Science ®Google Scholar
• Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol. 2008 Jul;83(7):547–553.
   PubMed Web of Science ®Google Scholar
• Novartis. NCT03264989: Pharmacokinetics and pharmacodynamics study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) patients with Vaso- Occlusive Crisis (VOC) [Internet]. [ cited 2021 Aug 17]. Available from: SEG110A2202 A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis. ** Effectiveness and value analysis of crizanlizumab compared with voxelotor and L-glutamine in sickle cell population.
   Google Scholar